Interaction Proteomics Identifies ERbeta Association with Chromatin Repressive Complexes to Inhibit Cholesterol Biosynthesis and Exert An Oncosuppressive Role in Triple-negative Breast Cancer.
Cancer biology
breast cancer
cell biology
cholesterol biosynthesis
estrogen receptor beta
interaction proteomics
label-free quantification
polycomb repressor complexes
transcriptional regulation
triple-negative breast cancer
tumor suppressors
Journal
Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
09
10
2019
revised:
27
11
2019
pubmed:
4
12
2019
medline:
11
11
2020
entrez:
4
12
2019
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC) is characterized by poor response to therapy and low overall patient survival. Recently, Estrogen Receptor beta (ERβ) has been found to be expressed in a fraction of TNBCs where, because of its oncosuppressive actions on the genome, it represents a potential therapeutic target, provided a better understanding of its actions in these tumors becomes available. To this end, the cell lines Hs 578T, MDA-MB-468 and HCC1806, representing the claudin-low, basal-like 1 and 2 TNBC molecular subtypes respectively, were engineered to express ERβ under the control of a Tetracycline-inducible promoter and used to investigate the effects of this transcription factor on gene activity. The antiproliferative effects of ERβ in these cells were confirmed by multiple functional approaches, including transcriptome profiling and global mapping of receptor binding sites in the genome, that revealed direct negative regulation by ERβ of genes, encoding for key components of cellular pathways associated to TNBC aggressiveness representing novel therapeutic targets such as angiogenesis, invasion, metastasis and cholesterol biosynthesis. Supporting these results, interaction proteomics by immunoprecipitation coupled to nano LC-MS/MS mass spectrometry revealed ERβ association with several potential nuclear protein partners, including key components of regulatory complexes known to control chromatin remodeling, transcriptional and post-transcriptional gene regulation and RNA splicing. Among these, ERβ association with the Polycomb Repressor Complexes 1 and 2 (PRC1/2), known for their central role in gene regulation in cancer cells, was confirmed in all three TNBC subtypes investigated, suggesting its occurrence independently from the cellular context. These results demonstrate a significant impact of ERβ in TNBC genome activity mediated by its cooperation with regulatory multiprotein chromatin remodeling complexes, providing novel ground to devise new strategies for the treatment of these diseases based on ligands affecting the activity of this nuclear receptor or some of its protein partners.
Identifiants
pubmed: 31792072
pii: S1535-9476(20)35077-5
doi: 10.1074/mcp.RA119.001817
pmc: PMC7000115
pii:
doi:
Substances chimiques
Chromatin
0
Estrogen Receptor beta
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-260Informations de copyright
© 2020 Alexandrova et al.
Références
Cancer Res. 2014 Mar 15;74(6):1705-17
pubmed: 24491801
Genome Biol. 2014;15(12):550
pubmed: 25516281
Trends Pharmacol Sci. 2017 Jan;38(1):92-99
pubmed: 27979317
Nat Commun. 2017 Jun 15;8:15840
pubmed: 28643774
EMBO Mol Med. 2013 Apr;5(4):488-508
pubmed: 23436775
J Cell Biochem. 2012 Jan;113(1):13-8
pubmed: 21898546
Exp Hematol. 2017 Apr;48:12-31
pubmed: 28087428
J Clin Invest. 2014 May;124(5):2260-76
pubmed: 24743148
Sci Data. 2018 Mar 06;5:180031
pubmed: 29509190
Cancers (Basel). 2019 Mar 07;11(3):null
pubmed: 30866496
Nat Rev Cancer. 2011 Jul 22;11(8):597-608
pubmed: 21779010
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
Nature. 2007 Nov 29;450(7170):712-6
pubmed: 18046409
Medicine (Baltimore). 2017 Dec;96(52):e9476
pubmed: 29384939
Mol Endocrinol. 2013 Sep;27(9):1429-41
pubmed: 23885094
J Cell Physiol. 2015 Nov;230(11):2683-94
pubmed: 25808524
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19506-11
pubmed: 18048329
Oncogene. 2017 Jan 5;36(1):133-145
pubmed: 27212032
Oncotarget. 2016 Mar 1;7(9):10373-85
pubmed: 26863572
Breast Cancer Res. 2012 Nov 16;14(6):R148
pubmed: 23158001
Mol Cell Proteomics. 2017 Apr;16(4 suppl 1):S187-S199
pubmed: 28196878
Genes Dev. 2010 Jul 1;24(13):1403-17
pubmed: 20595232
Cell Cycle. 2017 Feb 16;16(4):312-318
pubmed: 28055379
Stem Cell Reports. 2018 May 8;10(5):1596-1609
pubmed: 29606612
Sci Adv. 2019 Feb 06;5(2):eaav5590
pubmed: 30775443
Breast Cancer Res Treat. 2020 Jan;179(1):241-249
pubmed: 31571071
Biochimie. 2004 Nov;86(11):839-48
pubmed: 15589694
Elife. 2016 Jun 23;5:
pubmed: 27336722
J Biol Chem. 2002 Jan 11;277(2):1229-34
pubmed: 11704680
PLoS One. 2013 Aug 14;8(8):e71258
pubmed: 23967175
Stem Cells. 2015 Sep;33(9):2738-47
pubmed: 26077647
Int J Cancer. 2018 Sep 15;143(6):1388-1401
pubmed: 29633255
Mol Endocrinol. 2013 Oct;27(10):1762-75
pubmed: 23979844
Breast Cancer Res. 2016 Jun 01;18(1):58
pubmed: 27246191
Sci Adv. 2015 Jun 12;1(5):e1500447
pubmed: 26601204
Biomark Res. 2018 Mar 9;6:10
pubmed: 29556394
BMC Cancer. 2014 Oct 07;14:749
pubmed: 25288324
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13162-7
pubmed: 16938840
Hum Pathol. 2012 Oct;43(10):1638-44
pubmed: 22436627
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Ann Oncol. 2013 Aug;24(8):1986-93
pubmed: 23579816
Theranostics. 2019 Jan 1;9(1):34-47
pubmed: 30662552
Mol Cell Proteomics. 2016 Jul;15(7):2476-90
pubmed: 27114452
Oncogenesis. 2019 Aug 16;8(9):44
pubmed: 31420533
Nat Commun. 2018 Aug 23;9(1):3377
pubmed: 30139998
Cell Mol Life Sci. 2019 May;76(10):2015-2030
pubmed: 30725116
BMC Genomics. 2015 May 09;16:367
pubmed: 25956916
Biochem Biophys Res Commun. 2004 Apr 23;317(1):54-9
pubmed: 15047147
J Clin Invest. 1997 Mar 1;99(5):838-45
pubmed: 9062340
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:240-4
pubmed: 25433206
Tumor Microenviron. 2018 Apr-Jun;1(2):37-44
pubmed: 30740529
Front Endocrinol (Lausanne). 2018 Mar 22;9:120
pubmed: 29623068
Mol Cell Biol. 2001 Jan;21(1):343-53
pubmed: 11113208
J Cancer Res Clin Oncol. 2013 Sep;139(9):1489-98
pubmed: 23817696
Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9580-E9589
pubmed: 30257941
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
PLoS One. 2016 Apr 28;11(4):e0154471
pubmed: 27124117
Genes Dev. 2009 Nov 15;23(22):2578-91
pubmed: 19933148
Am J Clin Exp Urol. 2014 Oct 02;2(3):169-87
pubmed: 25374920
Cell Rep. 2019 Jun 25;27(13):3927-3938.e6
pubmed: 31242424
J Biol Chem. 2000 Feb 25;275(8):5308-17
pubmed: 10681503
Biomed Pharmacother. 2018 Jan;97:359-368
pubmed: 29091885
Photodiagnosis Photodyn Ther. 2018 Dec;24:185-191
pubmed: 30240926
Proteomics. 2015 Jun;15(11):1801-7
pubmed: 25604459
Trends Biochem Sci. 2017 Jul;42(7):531-542
pubmed: 28483375
Bioinformatics. 2015 Sep 1;31(17):2912-4
pubmed: 25964631
Genome Biol. 2017 Oct 6;18(1):189
pubmed: 29017520
Mol Cell Endocrinol. 2017 Jan 15;440:138-150
pubmed: 27889472
Am J Transl Res. 2016 Aug 15;8(8):3530-9
pubmed: 27648143
Br J Cancer. 2012 Jan 17;106(2):243-7
pubmed: 22187039
Mol Psychiatry. 2013 Jun;18(6):674-80
pubmed: 22665260
Mol Carcinog. 2018 Nov;57(11):1599-1607
pubmed: 30074275
Cancers (Basel). 2018 Dec 19;10(12):null
pubmed: 30572639
J Biol Chem. 2013 Aug 30;288(35):25038-52
pubmed: 23857583
Oncotarget. 2016 Jun 21;7(25):38270-38281
pubmed: 27223259
Nat Cell Biol. 2001 Jan;3(1):30-7
pubmed: 11146623
J Exp Clin Cancer Res. 2019 May 14;38(1):195
pubmed: 31088482
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2642-7
pubmed: 11867769
Cold Spring Harb Perspect Med. 2016 Nov 1;6(11):null
pubmed: 27638352